Economic Evaluation of Folate Supplementation during Methotrexate Treatment in Rheumatoid Arthritis

Journal of Rheumatology

Volumn 31, Issue 5, 2004, Pages 902-908

  Hartman, Margriet ^a   Van Ede, Annelies E ^a   Severens, Johan L ^a,b   Laan, Roland F J M ^a   Van De Putte, Leo B A ^a   Van Der Wilt, Gert Jan ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Cost benefit analysis; Folic acid; Folinic acid; Methotrexate; Rheumatoid arthritis

Indexed keywords

FOLIC ACID; FOLINIC ACID; METHOTREXATE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; ECONOMIC ASPECT; ECONOMIC EVALUATION; EUROPEAN QUALITY OF LIFE QUESTIONNAIRE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEALTH CARE COST; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALAISE; MALE; MENTAL DISEASE; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SIDE EFFECT; STATISTICAL ANALYSIS; SURVIVAL; VITAMIN SUPPLEMENTATION; WEIGHT REDUCTION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLIC ACID; HEALTH CARE COSTS; HEMATINICS; HUMANS; LEUCOVORIN; MALE; METHOTREXATE; MIDDLE AGED; PATIENT DROPOUTS; RHEUMATOLOGY; TIME FACTORS;

EID: 2342511514     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Weinblatt ME, Kaplan H, Germain BF, et al. Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. A thirty-six-week, double-blind trial. Arthritis Rheum 1990;33:330-8.
2. Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818-22.
3. Ward MM, Fries JF. Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981-1996. J Rheumatol 1998;25:408-16.
4. Alarcon GS, Tracy IC, Blackburn WD. Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum 1989;32:671-6.
5. Shiroky JB, Neville C, Esdaile JM, et al. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Arthritis Rheum 1993;36:795-803.
6. Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. Ann Intern Med 1994;121:833-41.
7. van Ede AE, Laan RFJM, Rood MJ, et al. Effect of folic or folinic acid supplementation on toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight-week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001;44:1515-24.
8. Dolan P. Modelling valuation for EuroQol Health States. Med Care 1997;35:1095-108.
9. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford Medical Publications; 1997.
10. Miedema HS, van der Linden SM, Rasker JJ, Valkenburg HA. National database of patients visiting rheumatologists in The Netherlands: the standard diagnosis register of rheumatic diseases. A report and preliminary analysis. Br J Rheumatol 1998;37:555-61.
11. Rutten FFH, Van Ineveld BM, Van Ommen R, Van Hout BA, Huijsman R. Kostenberekening bij gezondheidszorgonderzoek: richtlijnen voor de praktijk [Cost analysis in health care research: guidelines]. Utrecht: Uitgeverij Jan van Arkel; 1993.
12. Statistics Netherlands. Statistical yearbook 1997. Voorburg/Heerlen: Statistics Netherlands; 1997.
13. Rutten-Van Mölken MPMH, Van Doorslaer EKA, Van Vliet RCJA. Statistical analysis of cost outcomes in a randomised controlled clinical trial. Health Econ 1994;3:333-45.
14. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327-40.
15. Hilgeman CN, Koopmanschap MA, Rutten CF. Kosten van intensieve zorg in Nederland [Costs of intensive care in the Netherlands]. NTvG 1994;138:2252-6.
16. Morgan SL, Baggott JE, Vaughn WH, et al. The effect of folic acid supplementation on the toxicity of low dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990;33:9-18.
17. O'Dell JR. How is it best to treat early rheumatoid arthritis patients? Baillieres Best Pract Res Clin Rheum 2001;15:125-37.
18. Kremer JM. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med 2001;134:695-706.